| Jonathon Brian Posthumus, MD | |
|
511 Park Hill Dr, Fredericksburg, VA 22401-3377 | |
| (540) 371-5660 | |
| (540) 372-6920 |
| Full Name | Jonathon Brian Posthumus |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 17 Years |
| Location | 511 Park Hill Dr, Fredericksburg, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255536553 | NPI | - | NPPES |
| 1255536553 | Medicaid | VA | |
| VV7321A | Other | VA | MEDICARE PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 0101251294 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Washington Hospital | Fredericksburg, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allergy Partners Pllc | 7113822420 | 149 |
News Archive
With President Obama leading the charge against legalization of marijuana in what he calls a "new era of responsibility," a cultural change is taking place in California as more and more community activists join law enforcement officers, former drug addicts and faith-based leaders in support of the anti-marijuana cause.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Volunteers are to have chocolate delivered to their homes and be encouraged to eat 50g of it every day for eight weeks as part of a new research study.
A Public Health article published online today (9 July 2004) highlights how a lack of access to health information for health workers in resource-poor settings is a major obstacle to achieving the 2015 millennium goals for global health.
Is the science of diagnosing pain causing a number of pain sufferers to defend their honor? Research out of the University of Cincinnati is examining the diagnosis of pain that evades scientific testing, and the additional emotional suffering that can result for the patient.
› Verified 2 days ago
| Entity Name | Allergy Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740416247 PECOS PAC ID: 7113822420 Enrollment ID: O20091030000066 |
News Archive
With President Obama leading the charge against legalization of marijuana in what he calls a "new era of responsibility," a cultural change is taking place in California as more and more community activists join law enforcement officers, former drug addicts and faith-based leaders in support of the anti-marijuana cause.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Volunteers are to have chocolate delivered to their homes and be encouraged to eat 50g of it every day for eight weeks as part of a new research study.
A Public Health article published online today (9 July 2004) highlights how a lack of access to health information for health workers in resource-poor settings is a major obstacle to achieving the 2015 millennium goals for global health.
Is the science of diagnosing pain causing a number of pain sufferers to defend their honor? Research out of the University of Cincinnati is examining the diagnosis of pain that evades scientific testing, and the additional emotional suffering that can result for the patient.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathon Brian Posthumus, MD Po Box 603725, Charlotte, NC 28260-3725 Ph: (828) 575-2625 | Jonathon Brian Posthumus, MD 511 Park Hill Dr, Fredericksburg, VA 22401-3377 Ph: (540) 371-5660 |
News Archive
With President Obama leading the charge against legalization of marijuana in what he calls a "new era of responsibility," a cultural change is taking place in California as more and more community activists join law enforcement officers, former drug addicts and faith-based leaders in support of the anti-marijuana cause.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
Volunteers are to have chocolate delivered to their homes and be encouraged to eat 50g of it every day for eight weeks as part of a new research study.
A Public Health article published online today (9 July 2004) highlights how a lack of access to health information for health workers in resource-poor settings is a major obstacle to achieving the 2015 millennium goals for global health.
Is the science of diagnosing pain causing a number of pain sufferers to defend their honor? Research out of the University of Cincinnati is examining the diagnosis of pain that evades scientific testing, and the additional emotional suffering that can result for the patient.
› Verified 2 days ago
Dr. Ahmed Tariq Butt, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1300 Thornton St, Suite 200, Fredericksburg, VA 22401 Phone: 540-371-6810 Fax: 540-371-9154 | |
Andrew Kim, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1300 Thornton St, Suite 200, Fredericksburg, VA 22401 Phone: 540-371-6810 Fax: 540-371-9154 | |
Jonathan Daniel Mozena, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 511 Park Hill Drive, Fredericksburg, VA 22401 Phone: 540-371-5660 Fax: 540-372-6920 | |
Peter R. Smith, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 511 Park Hill Dr, Fredericksburg, VA 22401 Phone: 540-371-5660 Fax: 540-372-6920 | |
Mark A Wenger, M. D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 511 Park Hill Dr, Fredericksburg, VA 22401 Phone: 540-371-5660 Fax: 540-372-6920 | |
Dr. Nicholas A Klaiber, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 511 Park Hill Dr, Fredericksburg, VA 22401 Phone: 540-371-5660 Fax: 540-372-6920 |